The results were consistent with the preliminary results Eli Lilly shared in January, which disappointed investors.

Booming sales of its blockbuster incretin-based weight loss and diabetes drugs Mounjaro and Zepbound powered Eli Lilly (LLY) to a 45% jump in ...

US-based pharmaceutical company Eli Lilly is planning to launch Mounjaro, an anti-diabetes and weight loss drug in India by 2025 after regulatory approvals, reported News18 citing officials from ...

such as Zepbound and Mounjaro, over the last year. Eli Lilly on Thursday reported mixed results for the fourth quarter as sales of its blockbuster weight loss and diabetes drugs soared but it saw ...

Eli Lilly reported mixed results for the fourth quarter, even as demand for its blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro soared. The company's quarterly earnings ...

This is an enormous opportunity, and Lilly's clinical pipeline looks well positioned. Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now ...

(Reuters) -Eli Lilly ... of the drugs. Lilly said on a call with analysts that it still believed there was huge demand for its weight-loss drug Zepbound and diabetes treatment Mounjaro from ...

Eli Lilly reported mixed results for the fourth quarter as sales of its blockbuster weight loss and diabetes drugs soared but saw lower realized prices. Demand in the U.S. has far outpaced supply ...

While Novo Nordisk's Ozempic is the most mainstream GLP-1 medication, Eli Lilly (NYSE: LLY) has two blockbuster weight loss drugs of its own: Mounjaro and Zepbound. Mounjaro and Zepbound are by ...

Shares rise nearly 5% after upbeat forecast Drugmaker suggests demand for Zepbound and Mounjaro ... Lilly said on a call with analysts that it still believed there was huge demand for its weight ...